Ionis (IONS), Biogen Down on Ending Development of ALS Drug
ZacksIonis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.